« Return to News | Awards & Advancement

NW Bio appoints vet Rosskamp as CEO of German subsidiary

Friday, September 21, 2012 01:24 PM

Northwest Biotherapeutics, a biotech developing DCVaxR personalized immune therapies for cancer, has appointed former pharmaceutical industry executive Dr. Gunter Rosskamp as the CEO of the company's German subsidiary, Northwest Biotherapeutics, Gmbh.

Rosskamp brings extensive experience as a senior manager in the pharmaceutical sector.  He previously served as head of central nervous system (CNS) therapeutics at Schering (now part of Bayer) with responsibility for R&D and global marketing and sales of CNS products. He subsequently served as head of strategic business development at Schering, Rosskamp also served as vice president of life sciences and chemicals at the German Industrial Investment Council (IIC). More recently, he served as CEO of three biotech companies, including a company developing treatments for inflammatory and immune disorders, and two companies developing cell therapy products. 

Rosskamp succeeds Dr. Bernhard Faber, who served as the interim start-up CEO of Northwest Biotherapeutics' German subsidiary.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.